From Guidelines to Practice: Key Updates From 2021 HFSA

From Guidelines to Practice: Key Updates From 2021 HFSA

From Guidelines to Practice: Key Updates From 2021 HFSA

Overview of the recent updates presented at HFSA to guideline directed medical therapy (GDMT) in HFrEF and the implications for patient care.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Rapid initiation and up-titration of guideline-directed medical therapy (GDMT) is critical to achieve optimal patient outcomes in heart failure. This is particularly important in patients with multiple comorbidities and in pivotal situations to avoid stopping or lowering the dose of any of the four critical medicines that these patients must receive.

    Drs. Javed Butler, Ileana Piña, and Giuseppe Rosano will recap the data and the views that were presented at a symposium held in conjunction with the Heart Failure Society of America’s 2021 annual scientific meeting.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Ileana L. Piña, MD, MPH, FAHA, FACC

    Clinical Professor of Medicine
    College of Medicine
    Central Michigan University
    Mount Pleasant, MI

    Consulting Fees: Novartis, Relypsa

    Javed Butler, MD, MBA, MPH

    Professor & Chair, Department of Medicine
    University of Mississippi Medical Center
    Jackson, MS

    Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma

    Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
    Consultant Cardiologist and Professor of Cardiology
    Cardiovascular Clinical Academic Group
    St. George’s Hospitals NHS Trust University of London
    London, United Kingdom

    Dr. Rosano has nothing to disclose.

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • James Seternus, DO, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the key management recommendations of guideline-directed medical therapy (GDMT) for optimal pharmacologic therapy in patients with HFrEF
    • Evaluate the value of real-world data to inform HFrEF management across various pivotal situations of care
    • Implement strategies and clinical techniques to maximize GDMT and optimize RAASi dosing
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, primary care physicians, and all other professionals involved in the identification and treatment of HF.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free